Nanoparticle Vaccine Shows Potential as Immunotherapy to Fight Multiple Cancer Types – Controlled Environments Magazine
Controlled Environments Magazine |
Nanoparticle Vaccine Shows Potential as Immunotherapy to Fight Multiple Cancer Types
Controlled Environments Magazine Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types. The nanovaccine consists of tumor antigens – tumor proteins that can be recognized by the … Newly Discovered Nanoparticle Vaccines May Defeat Multiple Cancers [Video]University Herald |
Controlled Environments Magazine |
Nanoparticle Vaccine Shows Potential as Immunotherapy to Fight Multiple Cancer Types
Controlled Environments Magazine Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types. The nanovaccine consists of tumor antigens – tumor proteins that can be recognized by the … First-Ever Nanoparticle Vaccine Fights Different Types Of Cancer [VIDEO]University Herald |
Science Business |
World’s first gene therapy to be withdrawn in from market in Europe
Science Business Four and a half years after making history and getting European Medicines Agency approval for the first gene therapy in a regulated market, uniqure NV is throwing in the towel and will not apply for the license to be renewed when its expires on 25 October. Gene Therapy 2017 News: First Gene Therapy Drug Worth $1M, Withdrawn Due to Lack of DemandChristian Post EMA designates uniQure’s gene therapy for hemophilia a priorityLabiotech.eu (blog) UniQure’s haemophilia B therapy picks up PRIME statusPharmaTimes |
Science Business |
World’s first gene therapy to be withdrawn in from market in Europe
Science Business Four and a half years after making history and getting European Medicines Agency approval for the first gene therapy in a regulated market, uniqure NV is throwing in the towel and will not apply for the license to be renewed when its expires on 25 October. Gene Therapy 2017 News: First Gene Therapy Drug Worth $1M, Withdrawn Due to Lack of DemandChristian Post EMA designates uniQure’s gene therapy for hemophilia a priorityLabiotech.eu (blog) UniQure’s haemophilia B therapy picks up PRIME statusPharmaTimes |
Nature.com |
California’s $3-billion bet on stem cells faces final test
Nature.com When California voters approved US$3 billion in funding for stem–cell research in 2004, biologists flocked to the state, and citizens dreamed of cures for Parkinson’s disease and spinal-cord injuries. Now, the pot of money — one of the biggest state … Ethics should partner with science in research and developmentIdaho Mountain Express and Guide Aspen Institute now offering regenerative STEM Cell therapyMilTech |